Whoa! What Just Happened to My Stock?

Resist the urge to high-five everyone in the cubicles next to you. Your stock may have just strapped on a rocket pack and taken off for the moon, but smart investors won't celebrate until they know that upward leap was justified. Without a fundamental basis for the bounce, these stocks can quickly make the return trip down.

Is now the time to lock in profits, or is this just the first step toward even higher valuations down the road? Let's examine several stocks that just hit the afterburners, and see whether they're truly headed into orbit.

Stock

CAPS Rating (out of 5)

Past Week's Change

KV Pharmaceuticals (NYSE: KV-A  )

**

108.76%

Emcore (Nasdaq: EMKR  )

**

37.70%

Timberland (NYSE: TBL  )

***

33.89%

Although it may have felt like two steps forward, one step back at times, the market has risen more than 1% over the past week, as the market ignore rising inflation and higher jobless claims, preferring instead to focus on an ebullient manufacturing report. So stocks that have surged upwards by larger percentages are even bigger deals.

New frontiers in investing
With its stock soaring after FDA approval for its drug designed to reduce the risk of preterm birth, KV Pharmaceuticals figures it's a good time to raise some cash. The biotech will be raising $32 million in a private placement and will be setting up a $130 million financing facility, too. The funds it receives from the stock sale will be used in part to launch the drug Makena.

Under development with Hologic (Nasdaq: HOLX  ) and previously known as Gestiva, Makena is designed to reduce the risk of premature birth in women who have a history of preterm birth. It was only a month ago that analysts were wondering whether KV could survive financially after the FDA delayed a decision on the drug. It came back quickly, however, with an approval and KV's stock has been on a tear since, up 420% this month alone (and it's up another 10% as of this writing). It's doubtful it will remain hidden from Wall Street's sight much longer.

Whatever the merits of the treatment, the sudden surge in price has CAPS All-Star EnigmaDude thinking the stock has come too far, too fast and is ready for a fall. But the wider CAPS community is looking for the stock to outperform the broad market averages with 92% of the more than 400 members rating the biotech giving it the thumbs up.

You can add your own opinion on the KV Pharmaceuticals CAPS page on whether you think EnigmaDude is premature in calling for it to return to earth.

Making it to the big time
Although Emcore isn't ripping as high as KV, the optical networking specialist is enjoying the updraft from a superb first quarter earnings report. Revenues jumped 23% higher generating a 36% increase in profits as its photovoltaic segment saw greater sales sequentially and year over year and wider margins. Even rival JDS Uniphase (Nasdaq: JDSU  ) is seeing the value in the solar sector as it branches out from the telecommunications market, and its shares are higher, too.

It's a rising tide that's lifting all boats, with Emcore, Ciena (Nasdaq: CIEN  ) , and Finisar all rallying higher. Yet Emcore also reported that its PV backlog was down 32% as it completed several projects and experienced a delay in a new order from an international customer. Look to its concentrating photovoltaic (CPV) joint venture, though, as it begins to gain traction.

Follow along with EMCORE by adding the stock to your watchlist and have all the Foolish news and analysis gathered together for you in one place.

The sky's the limit
Boot maker Timberland was another company kicking analysts' butt with its most recent quarterly report, with earnings that more than doubled over the year-ago period. While Wall Street was shocked -- shocked! -- that a simple footwear company could produce enormous growth, the Fool's Alyce Lomax had chosen Timberland as her inaugural pick for her Rising Stars portfolio.

While the run-up in the stock gives it a pretty hefty market premium, compared to similar situated Deckers Outdoor (Nasdaq: DECK  ) it is priced right in line with its peer. Wolverine Worldwide, however, with equally impressive quarterly results, seems downright cheap at just 17 times trailing earnings and a multiple below 14 times forward estimates.

What sets Timberland apart for CAPS member gweech is that its shoes bundles both functionality and style:

Solid company and solid products. TBL shoes last forever and ever and ever. The US will always have an athletic outdoor bent to it and people will always buy this clothing at stores like REI. Unlike pure designer brands, TBL has both utility and fashion built into one package.

Walk over to the Timberland CAPS page and let us now whether it's time to give it the boot from our portfolio after this big run, or should we be adding more?

Going into orbit
That's why it pays to start your own research on these stocks on Motley Fool CAPS, where you can read a company's financial reports, scrutinize key data and charts, and examine the comments your fellow investors have made, all from the stock's CAPS page. Then you can decide for yourself whether your stock's headed for reentry, or off to infinity and beyond.

Timberland is a Motley Fool Stock Advisor recommendation. The Fool owns shares of Timberland. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. 

Fool contributor Rich Duprey does not have a financial position in any of the stocks mentioned in this article. You can see his holdings here. The Motley Fool has a disclosure policy.


Read/Post Comments (2) | Recommend This Article (13)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On February 18, 2011, at 3:40 PM, peterod4 wrote:

    kv is fundamentally cheap even if you believe the worst case scenario for its new drug. The company was a $30 stock before it screwed up and things are now almost fixed and they have Makena.... Institutions are dying to get in here but not to many sellers in this party so the stock closes up every day. Will probably settle in the $15 dollar range over the next few weeks imo.....

  • Report this Comment On February 23, 2011, at 8:58 PM, samuel2011 wrote:

    Why did KVA lose over 25% of its stock price in the last 2 days?

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1444522, ~/Articles/ArticleHandler.aspx, 11/27/2014 3:00:33 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement